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“Abstract.” With the aim to find out the structural features for the MAO inhibitory activity and 
selectivity, in the present communication we report the design, synthesis and pharmacological 
evaluation of a new series of coumarin derivatives with 4-methyl or cycloalkene or benzene ring 
condensed in the 3,4 position. The substituents in this new scaffold were introduced in the 5, 7 and/or 8 
positions of the coumarin moiety. The synthesized compounds 1-13 were evaluated as MAO A and B 
inhibitors using clorgyline and selegiline, respectively, as reference inhibitors, showing, most of them, 
activities in the nanomolar range. Compounds 6 (IC50 = 1.18 nM) and 10 (IC50 = 1.48 nM), show higher 
activity than selegiline (IC50 = 19.60 nM), and high MAO-B selectivity with 100-fold and 1600-fold 
inhibition levels, with respect to the MAO-A isoform.  
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Introduction 
Mono amine oxidases (MAOs) are flavoenzymes bound to the outer mitochondrial membrane and 
are responsible for the oxidative deamination of neurotransmitters and dietary amines.1,2 Two isoforms, 
namely MAO-A and MAO-B, have been identified on the basis of their amino acid sequences, three-
dimensional structure, substrate preference and inhibitor selectivity.3,4 MAO-A has a higher affinity for 
 
2
serotonin and noradrenaline whereas MAO-B preferentially deaminates phenylethylamine and 
benzylamine. These properties determine the clinical importance of MAO inhibitors. Selective MAO-A 
inhibitors such as clorgyline (irreversible) and moclobemide (reversible) are used in the treatment of 
neurological disorders such as depression,5,6 whereas the selective and irreversible MAO-B inhibitors 
such as selegiline and rasagiline are useful in the treatment of Parkinson’s7,8 and Alzheimer’s 
diseases.9,10  
All of these aspects have led to an intensive search for novel MAO inhibitors (MAOIs) and this effort 
has increased considerably in recent years. However, earlier MAOIs introduced into clinical practice 
were abandoned due to adverse effects, such as hepatotoxicity, orthostatic hypotension and the so-called 
“cheese effect”, which was characterized by hypertensive crisis.11,12  
In recent years, a broad consensus has been reached concerning the necessity for a search for novel 
MAOIs and the study of their interaction with MAOs.13-15 The major breakthrough has been brought 
about by the crystallization of hMAO-B with different inhibitors.16 This fact explains the subsequent 
elucidation and determination of the 3D structure of the active site of hMAO-A3 and opened new 
possibilities for the design of more selective and reversible drugs and facilitated the computer-assisted 
development of more selective inhibitors. Molecular docking calculations,17,18 comparative molecular 
field analysis (CoMFA)19,20 as well as QSAR methods are among the computational methods that have 
been used to predict MAOIs. Respect of this, in previous works our group has developed a new QSAR 
methodology called MARCH-INSIDE21,22 methodology to seek theoretical models for the prediction of 
different biological activities. Applying this method is possible to predict the in vitro MAO A/B 
inhibitory activity of new series of coumarin derivatives. 
A specific way to new lead discovery involves several general common steps when used in terms of a 
QSAR: (a) construction of a suitable molecular database of compounds that either show the property in 
question or do not; (b) calculation of the molecular descriptors; (c) construction of the model; (d) 
estimation of the biological activity using QSAR; (e) synthesis and characterization of selected 
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compounds; (f) assay of the candidate compounds in order to corroborate the predicted biological 
activity.  
The coumarin analogs are a family of natural and/or synthetic compounds with different 
pharmacological activities, one of which is MAO inhibitory activity.23,24 In many cases, it is known that 
activity and selectivity are determined by the nature of the substituents at the 7- and the 4/3-positions.25-
27 On the other hand, in a previous investigation28 we developed QSAR studies for the MAO-A 
inhibitory activity in a series of coumarin derivatives and found that the most active compounds were 
the 7-acetonyloxy-substituted compounds, which showed higher activity than their cyclic analogs and 
were also more active than the 7-hydroxy precursors. 
 
Results and discussion 
The theoretical QSAR model was created using a very large data base of heterogeneous compounds 
in which activities were measured in cellular lines from different organs and species. The model 
classified correctly 3222 out of 3408 inputs (94.5%) and was then used to predict the activity of 13 
compounds in our designed coumarin library. All of the active compounds were correctly predicted by 
the model, and a total of 81.82% and 72.73% compounds were correctly predicted as MAO-A and 
MAO-B inhibitors, respectively.  
On the basis of the QSAR model information – and with the aim of exploring the structure-affinity 
and MAO-A/B selectivity relationships – in the present work we designed a series of 13 coumarin 
derivatives (Table 1) that include the aforementioned chemical diversity with particular attention paid 
to the most interesting 7-(β-ketoether)coumarin derivatives. The compounds were synthesized according 
to Scheme 1 and details are given in the Experimental section. 
The SAR analysis seems to corroborate the importance of the structural requirements of the 
substituents in the coumarin moiety in order to achieve good activity and MAO-A/B selectivity, as 
indicated in the literature.24-26 The 7-hydroxy derivatives have been shown to be inactive, even with the 
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introduction of bulky substituents in any other positions of the coumarin (compounds 1 and 2). The 
introduction of acetonyl/bromoallyloxy groups in the 7-position of the coumarin yielded compounds (3 
to 10) with greater MAO-A and MAO-B inhibitory activity. The substitution in the 5 position 
(compounds 11 and 12) of the coumarin ring leads to the activity loss either in the case of the ketoether 
substituent or the cyclation to the corresponding furocoumarin 13. Finally, the most relevant findings 
are the introduction of bulky groups such as cyclohexyl or phenyl in the 3,4-positions of the 7-acetonyl 
derivatives increased both MAO-A and MAO-B inhibitory activities with concomitant loss of 
selectivity, whereas replacement of the acetonyl substituent at position 7 by the bromoallyloxy group 
resulted in compounds 6 and 10, which had very high MAO-B inhibitory activity (IC50 of about 1.2 nM 
and 1.5 nM) and the highest MAO-B selectivity (approximately 100-fold and 1600-fold) with respect to 
the MAO-A isoform.  
















Compound R3 R4 R5 R7/(CH2)n R8 
1 –(CH2)3– H OH Me 
2 –(CH2)4– H OH Me 
3 –(CH2)3– H MeCOCH2O– Me 
4 –(CH2)4– H MeCOCH2O– Me 
5 –(CH2)4– H MeCOCH2O– OMe 
6 –(CH2)3– H CH2C(Br)CH2– Me 
7 –(CH2)4– H CH2C(Br)CH2– Me 
8 Ph H MeCOCH2O– Me 
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9 Ph H MeCOCH2O– OMe 
10 Ph H CH2C(Br)CH2– Me 
11 H CH3 OH OMe H 
12 H CH3 MeCOCH2O– OMe H 
13 - - - - 
 
Chemistry. The coumarin derivatives 1-13 were efficiently synthesized according to the synthetic 
protocol outlined in Scheme 1. 
Pechmann condensation of 2-alkyl resorcinol with the corresponding ketoester afforded the 3,4-
cyclopentene/cyclohexene-7-hydroxy coumarins 1, 2 and 11. The Williamson reaction of the 7-
hydroxycoumarins 1, 2 and 11 with 2-chloroketones or 2,3-dibromopropene gave the corresponding 
ethers 3, 4, 6, 7 and 12. Compounds 4, 5 and 7 were oxidized with DDQ to give the corresponding 3,4-
benzocoumarin derivatives 8–10. Finally, the compound 12 was treated in basic conditions to obtain the 






































Scheme 1. Synthetic strategy for prepared compounds 
 
MAO inhibition assay. The potential effects of the test drugs on hMAO activity were investigated by 
measuring their effects on the production of hydrogen peroxide from p-tyramine (a common substrate 
for both hMAO-A and hMAO-B), using the 10-acetyl-3,7-dihydroxyphenoxazine as reagent and 
microsomal MAO isoforms prepared from insect cells (BTI-TN-5B1-4) infected with recombinant 
baculovirus containing cDNA inserts for hMAO-A or hMAO-B. 
The production of H2O2 catalyzed by MAO isoforms can be detected using the previously mentioned 
reagent, a non-fluorescent, highly sensitive and stable probe that reacts with H2O2 in the presence of 
horseradish peroxidase to produce a fluorescent product: resorufin. In this study hMAO activity was 
evaluated using the above method following the general procedure described previously by us.29 
The tested drugs (new compounds and reference inhibitors) inhibited the control enzymatic MAO 
activities and the inhibition was concentration dependent. The corresponding IC50 values and MAO-B 
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selectivity ratios [IC50 (MAO-A)]/[IC50 (MAO-B)] are shown in Table 2. 
 
Table 2. In vitro evaluation of MAO inhibitory activities of compounds 1–13 and reference inhibitors 
 MAO-A MAO-B MAO-A/B 
Compound IC50 IC50  
1 ** ** – 
2 60.11 ± 3.47 µM ** <0.60c 
3 235 ± 18.52 nMb 165 ± 7.04 nM 1.42 
4 3.78 ± 0.34 µMa 17.3 ± 1.48 µM 0.22 
5 396 ± 16.63 nMa 12.12 ± 1.03 µM 0.033 
6 130 ± 11.77 nMa 1.18 ± 0.15 nM 110 
7 695 ± 28.54 nMb 236 ± 5.03 nM 2.94 
8 2.56 ± 0.14 µMa 28.13 ± 1.14 µM 0.091 
9 11.93 ± 0.61 µM 9.36 ± 0.26 µM 1.27 
10 2.38 ± 0.06 µMa 1.49 ± 0.12 nM 1,597 
11 >100 µM >100 µM – 
12 65,12 µM >100 µM – 
13 * * – 
Clorgyline 4.46 ± 0.32 nMa 61.35 ± 1.13 µM 0.00007 
Selegiline 67.25 ± 1.02 µMa 19.60 ± 0.86 nM 3,431 
Iproniazide 6.56 ± 0.76 µM 7.54 ± 0.36 µM 0.87 




Each IC50 value is the mean ± S.E.M. from five experiments (n = 5). 
* Inactive at 1 mM (highest concentration tested). 
** Inactive at 100 µM (highest concentration tested). At higher concentrations the compounds 
precipitate. 
*** Inactive at 50 µM (highest concentration tested). At higher concentrations the compounds 
precipitate. 
a,bLevel of statistical significance: bP< 0.01 or bP< 0.05 versus the corresponding IC50 values obtained 
against MAO-B as determined by ANOVA/Dunnett´s. 
cValues obtained under the assumption that the corresponding IC50 against MAO-A/B is the highest 
concentration tested.  
 
Conclusions 
In summary, we have developed good theoretical models to predict inhibitory MAO activity. On the 
basis of this model we have found new coumarin derivatives with inhibitory activity comparable to 
those of clorgyline and selegiline, respectively, which are used as reference inhibitors and have a very 
high MAO-A and MAO-B selectivity. These findings have encouraged us to continue our investigations 




Chemistry. Melting points were determined using a Reichert Kofler thermopan or in capillary tubes 
on a Büchi 510 apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer 1640FT 
spectrophotometer. 1H and 13C NMR spectra were recorded on a Bruker AMX spectrometer at 300 and 
75.47 MHz, respectively, using TMS as internal standard (chemical shifts in δ values, J in Hz). Mass 
spectra were obtained using a Hewlett Packard 5988A spectrometer. Elemental analyses were 
performed using a Perkin-Elmer 240B microanalyser and were within ±0.4% of calculated values in all 
cases. Silica gel (Merck 60, 230–00 mesh) was used for flash chromatography (FC). Analytical thin 
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layer chromatography (TLC) was performed on plates precoated with silica gel (Merck 60 F254, 0.25 
mm). 
General procedure for the preparation of 3,4-cycloalkane-7-hydroxycoumarins (1, 2, 11). 2-
Methylresorcinol (80.554 mmol) was dissolved in 12M H2SO4 (120 mL). The appropriate ethyl 2-
oxocycloalkanecarboxylate (96.65 mmol) was added and the solution was stirred at room temperature 
for 15 h. The reaction mixture was then poured into ice/water (100 mL) and the precipitate was 
recovered by filtration and washed with water to yield the desired compound, which was purified by 
crystallization. 
8-Methyl-3,4-cyclopentene-7-hydroxycoumarin (1). Yield 82%; mp 259 ºC (EtOH); 1H NMR 
(DMSO-d6) 2.07 (m, 2H, CH2CH2CH2), 2.16 (s, 3H, Me-C8), 2.70 (t, J = 7.3, 2H), 2.98 (t, J = 7.5, 2H), 
6.84 (d, J = 8.4, 1H, H-6), 7.24 (d, J = 8.4, 1H, H-5), 10.30 (s, 1H, OH); 13C NMR (DMSO-d6) 8.21 
(Me-C8), 22.03 (CH2CH2CH2), 29.88, 31.60, 110.57 (C8), 110.63, 111.66 (C6), 121.89, 123.00 (C5), 
153.35, 157.02, 158.25, 159.46 (C2); IR 3362, 2920, 1682, 1577, 1275, 1081, 812; MS m/z 217 ([M + 
1]+, 14), 216 (M+, 100), 188 (58), 187 (65), 145 (6), 128 (3). Anal. (C13H12O3) C, H. 
8-Methyl-3,4-cyclohexene-7-hydroxycoumarin (2). Yield 71%; mp 279–280 ºC (EtOH); 1H NMR 
(DMSO-d6) 1.69 (m, 4H, CH2(CH2)2CH2), 2.11 (s, 3H, Me-C8), 2.35 (m, 2H), 2.64 (m, 2H), 6.79 (d, J = 
8.6, 1H, H-6), 7.30 (d, J = 8.6, 1H, H-5), 10.16 (s, 1H, OH); 13C NMR (DMSO-d6) 8.30 (Me-C8), 
21.29, 21.61, 23.78 (CH2-C4), 24.95, 110.61 (C8), 111.87 (C6), 112.25, 118.27, 121.78 (C5), 148.13, 
151.40, 157.94, 161.45 (C2); IR 3275, 2932, 1676, 1606, 1374, 1266, 1102, 804; MS m/z 231 ([M + 1]+, 
15), 230 (M+, 100), 215 (47), 202 (33), 174 (60). Anal. (C14H14O3) C, H. 
5-Hydroxy-4-methyl-7-methoxycoumarin (11). Yield 50%; mp 260 ºC (EtOH); 1H NMR (DMSO-
d6) 2.50 (d, J = 1.1, 3H, Me), 3.76 (s, 3H, MeO), 5.93 (d, J = 1.1, 1H, H-3), 6.31 (d, J = 2.4, 1H, H-6), 
6.42 (d, J = 2.4, 1H, H-8), 10.70 (s, 1H, OH); 13C NMR (DMSO-d6) 23.71 (Me-C4), 55.90 (MeO-C8), 
93.11 (C8), 98.40 (C6), 103.52 (C4a), 110.22 (C3), 155.21 (C4), 156.83 (C8a), 158.11 (C5), 160.31 
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(C2), 162.62 (C7); IR 3168, 2940, 1684, 1629, 1598, 1396, 1288, 1209, 1074, 846; MS m/z 207 ([M + 
1]+, 13), 206 (M+, 100), 178 (86), 163 (69), 135 (10). Anal. (C11H10O4) C, H. 
General procedure for the preparation of oxoether derivatives 3, 4, 5, 6, 7 and 12. To a solution 
of the substituted 7-hydroxycoumarin derivatives 1, 2 or 11 (62 mmol) in dry acetone (300 mL) were 
added K2CO3 (4 g) and the corresponding 2-chloroketones or 2,3-dibromopropene (120 mmol). The 
mixture was heated under reflux for 24 h. The mixture was cooled and the solid residue was filtered off. 
The solvent was removed under reduced pressure and the crude product was purified by FC and/or 
crystallization to give the desired compound.  
7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin (3). 76%; mp 144 ºC; 1H NMR (CDCl3) 2.18 
(m, 2H, CH2CH2CH2), 2.34 (s, 3H, MeCO), 2.38 (s, 3H, Me-C8), 2.87 (t, J = 7.5, 2H), 3.01 (t, J = 5.9, 
2H), 4.63 (s, 2H, CH2O), 6.64 (d, J = 8.6, 1H, H-6), 7.21 (d, J = 8.6, 1H, H-5); 13C NMR (CDCl3) 9.01 
(Me-C8), 22.86 (CH2CH2CH2), 27.10 (MeCO), 30.76, 32.40, 73.74 (CH2O), 107.73 (C6), 113.69, 
114.87, 122.98 (C5), 125.29, 153.72, 156.73, 157.98, 160.78 (C2), 205.29 (MeCO); IR 2956, 1733, 
1706, 1615, 1376, 1286, 1120, 805; MS m/z 273 ([M + 1]+, 18), 272 (M+, 100), 229 (46), 215 (43), 187 
(33), 128 (44). Anal. (C16H16O4) C, H. 
7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin (4). Yield 79%; mp 161–162 ºC; 1H NMR 
(CDCl3) 1.81 (m, 4H, CH2(CH2)2CH2), 2.33 (s, 3H, MeCO), 2.37 (s, 3H, Me-C8), 2.54 (m, 2H), 2.72 
(m, 2H), 4.62 (s, 2H, CH2O), 6.64 (d, J = 8.8, 1H, H-6), 7.34 (d, J = 8.8, 1H, H-5); 13C NMR (CDCl3) 
8.39 (Me-C8), 21.43, 21.67, 23.89, 25.21, 26.70 (MeCO), 73.40 (CH2O), 107.18 (C6), 114.24 (C8), 
114.79, 120.97, 121.08 (C5), 147.13, 151.22, 157.09, 162.05 (C2), 205.13 (MeCO); IR 2942, 1738, 
1698, 1605, 1416, 1292, 1025, 803; MS m/z 287 ([M + 1]+, 38), 286 (M+, 100), 271 (12), 258 (5), 243 
(60), 230 (21). Anal. (C17H18O4) C, H. 
7-Acetonyloxy-3,4-cyclohexene-8-methoxycoumarin (5). Yield 71%; mp 141–143 ºC; 1H NMR 
(CDCl3) 1.82 (m, 4H, CH2(CH2)2CH2), 2.31 (s, 3H, MeCO), 2.55 (m, 2H), 2.72 (m, 2H), 4.01 (s, 3H, 
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MeO), 4.70 (s, 2H, CH2O), 6.73 (d, J = 8.9, 1H, H-6), 7.22 (d, J = 8.9, 1H, H-5); 13C NMR (CDCl3) 
21.90, 22.18, 24.53, 25.86, 27.12 (MeCO), 62.23 (MeO), 74.67 (CH2O), 110.50 (C6), 116.66, 118.65 
(C5), 122.22, 137.18, 147.03, 147.70, 152.83, 161.85 (C2), 205.22 (MeCO); IR 2941, 1734, 1697, 1609, 
1302, 1115, 795; MS m/z 302 (M+, 100), 259 (26), 245 (55), 214 (17), 128 (14). Anal. (C17H18O5) C, H. 
7-(β-Bromoallyloxy)-3,4-cyclopentene-8-methylcoumarin (6). Yield 78%; mp 140 ºC; 1H NMR 
(CDCl3) 2.19 (m, 2H, CH2CH2CH2), 2.38 (s, 3H, Me-C8), 2.90 (t, J = 7.5, 2H, CH2-C4), 3.03 (t, J = 7.6, 
2H, CH2-C3), 4.72 (s, 2H, CH2O), 5.71 (d, J = 2.1, 1H, C=CH), 6.01 (d, J = 2.1, 1H, C=CH), 6.77 (d, J 
= 8.6, 1H, H-6), 7.23 (d, J = 8.6, 1H, H-5); 13C NMR (CDCl3) 8.61 (Me-C8), 22.56 (CH2CH2CH2), 
30.40 (CH2-C4), 32.07 (CH2-C3), 72.02 (CH2O), 108.09 (C6), 113.26 (C8), 114.81, 118.00 (CH2=C), 
122.47 (C5), 124.94, 126.52, 153.40, 156.40, 157.63, 160.58 (C2); IR 2919, 1716, 1611, 1373, 1282, 
1109, 803; MS m/z (%): 336 ([M + 2]+, 12), 335 (M+, 12), 255 (76), 215 (29), 187 (100), 128 (15). Anal. 
(C16H15BrO3) C, H. 
7-(β-Bromoallyloxy)-3,4-cyclohexene-8-methylcoumarin (7). Yield 76%; mp 135–136 ºC; 1H 
NMR (CDCl3) 1.82 (m, 4H, CH2(CH2)2CH2), 2.35 (s, 3H, Me-C8), 2.56 (m, 2H, CH2-C4), 2.72 (m, 2H, 
CH2-C3), 4.71 (s, 2H, CH2O), 5.76 (d, J = 1.6, 1H, C=CH), 6.01 (d, J = 1.6, 1H, C=CH), 6.75 (d, J = 
8.8, 1H, H-6), 7.35 (d, J = 8.8, 1H, H-5); 13C NMR (CDCl3) 8.78 (Me-C8), 21.86 (CH2-CH2C3), 22.11 
(CH2-CH2C4), 24.31 (CH2-C3), 25.65 (CH2-C4), 72.36 (CH2O), 108.32 (C6), 114.80 (C8), 115.04, 
118.36 (CH2=C), 121.26, 121.35 (C5), 127.03, 147.64, 151.57, 157.47, 162.60 (C2); IR 3071, 2935, 
1708, 1605, 1114, 755; MS m/z 350 ([M + 2]+, 4), 349 (M+, 22), 269 (89), 229 (100), 201 (58), 187 (40). 
Anal. (C17H17BrO3) C, H. 
5-Acetonyloxy-4-methyl-7-methoxycoumarin (12). Yield 95%; mp 236–237 ºC; 1H NMR (CDCl3) 
2.28 (s, 3H, MeCO), 2.64 (d, J = 1.2, 3H, Me-C4), 3.83 (s, 3H, MeO), 4.66 (s, 2H, CH2O), 6.01 (d, J = 
1.2, 1H, H-3), 6.11 (d, J = 2.3, 1H, H-8), 6.48 (d, J = 2.3, 1H, H-6); 13C NMR (CDCl3) 24.58 (Me-C4), 
26.70 (MeCO), 55.82 (MeO) 73.29 (CH2O), 94.27 (C8), 96.41 (C6), 105.08, 111.99 (C3), 154.05, 
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156.93, 157.23, 160.85, 162.58 (C2), 202.45 (MeCO); IR 2945, 1733, 1625, 1592, 1385, 1336, 1118, 
847; MS m/z 263 ([M + 1]+, 15), 262 (M+, 100), 234 (45), 219 (20), 205 (44), 191 (20). Anal. 
(C14H14O5) C, H. 
General procedure for the preparation of 3,4-benzocoumarins 8–10. To a solution of the acyclic 
ether 4, 530 or 7 (0.30 mmol) in toluene (15 mL) was added DDQ (0.60 mmol). The solution was heated 
under reflux for 5 h. The mixture was cooled, the precipitate filtered off and the solvent evaporated 
under reduced pressure. The resulting residue was purified by FC to give the desired compound. 
3,4-Benzo-7-acetonyloxy-8-methylcoumarin (8). Yield 64%; mp 172–174 ºC; 1H NMR (CDCl3) 
2.35 (s, 6H, Me-C8, MeCO), 4.60 (s, 2H, CH2O), 6.63 (d, J = 8.8, 1H, H-6), 7.46 (m, 1H, CH-CHC3), 
7.73 (m, 2H, H-5, CH-CHC4), 7.91 (d, J = 8.0, 1H, CH C4), 8.28 (d, J = 7.9, 1H, CH-C3); 13C NMR 
(CDCl3) 8.45 (Me-C8), 26.67 (MeCO), 73.19 (CH2O), 107.43 (C6), 111.95, 114.95, 119.72, 120.44 
(CH-C4), 121.12 (CH -CHC3), 127.72 (C5), 130.19 (CH-C3), 134.60 (CH-CHC4), 134.94, 150.15, 
156.95, 161.13 (C2), 204.98 (MeCO); IR 2925, 1716, 1607, 1468, 1284, 1125, 766; MS m/z 283 ([M + 
1]+, 18), 282 (M+, 100), 239 (60), 225 (43), 181 (51), 152 (47). Anal. (C17H14O4) C, H. 
3,4-Benzo-7-acetonyloxy-8-methoxycoumarin (9). Yield 56%; mp 172–174 ºC; 1H NMR (CDCl3) 
2.33 (s, 3H, MeCO), 4.05 (s, 3H, MeO), 4.72 (s, 2H, CH2O), 6.80 (d, J = 9.0, 1H, H-6), 7.53 (t, J = 8.1, 
1H, CH -CHC3), 7.70 (d, J = 9.0, 1H, H-5), 7.78 (t, J = 7.7, 1H, CH-CHC4), 7.99 (d, J = 8.0, 1H, CH-
C4), 8.36 (d, J = 7.9, 1H, CH-C3); 13C NMR (CDCl3) 27.01 (MeCO), 62.15 (MeO), 74.62 (CH2O), 
110.94 (C6), 114.12, 118.00 (CH-C4), 120.50, 121.88 (C5), 128.76 (CH- CHC3), 131.04 (CH-C3), 
135.29, 135.36 (CH-CHC4), 137.94, 146.26, 152.78, 161.07 (C2), 205.12 (MeCO); IR 2935, 1730, 
1608, 1475, 1304, 1121, 812; MS m/z 299 ([M + 1]+, 18), 298 (M+, 100), 255 (27), 241 (67), 197 (25), 
170 (19). Anal. (C17H14O5) C, H. 
3,4-Benzo-7-(b-bromoallyloxy)-8-methylcoumarin (10). Yield 82%; mp 128 ºC; 1H NMR (CDCl3) 
2.38 (s, 3H, Me-C8), 4.72 (s, 2H, CH2O), 5.72 (d, J = 1.9, 1H, C=CH), 6.03 (d, J = 1.9, 1H, C=CH), 
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6.80 (d, J = 8.8, 1H, H-6), 7.49 (m, 1H, CH-CHC4), 7.78 (m, 1H + 1H, CH-CHC3 + H-5), 7.98 (d, J = 
8.0, 1H, CH-C3), 8.34 (d, J = 8.0, 1H, CH-C4); 13C NMR (CDCl3) 8.95 (Me-C8), 72.33 (CH2O), 108.68 
(C6), 112.36, 115.67, 118.39 (C=CH2), 120.25, 120.84 (CH-C4), 121.63 (CH-CHC3), 127.01, 128.18 
(C5), 130.75 (CH-CHC4), 135.12 (CH-C3), 135.57, 150.66, 157.49, 161.78 (C2); IR 2921, 1726, 1608, 
1470, 1283, 1115, 891, 766; MS m/z 347 ([M + 2]+, 2), 345 (M+, 12), 344 (13), 265 (60), 225 (100), 171 
(17). Anal. (C17H13BrO3) C, H. 
Preparation of 7-Methoxy-4-methyl-4'-methylfuro[5,6-g]coumarin 13. To a solution of the 
corresponding ketoether 12 (3.39 mmol) in ethyl alcohol (200 mL) was added 0.1M NaOH (200 mL). 
The mixture was heated under reflux for 12 h, acidified with HCl and concentrated to half volume and 
left overnight. The resulting precipitate was filtered off and purified by FC to give the desired 
compound (13). Yield 52%; mp 212 ºC; 1H NMR (CDCl3) 2.35 (d, J = 1.3, 3H, Me-C4'), 2.68 (d, J = 
1.2, 3H, Me-C4), 3.95 (s, 3H, MeO), 6.09 (d, J = 1.2, 1H, H-3), 6.61 (s, 1H, H-8), 7.35 (d, J = 1.3, 1H, 
H-5'); 13C NMR (CDCl3) 9.71 (Me-C4'), 21.93 (Me-C4), 55.92 (MeO), 93.64 (C8), 102.00, 111.10 (C3), 
115.34, 116.22, 140.61 (C5’), 152.26, 153.72, 153.89, 157.42, 161.45 (C2); IR 2989, 1717, 1619, 1606, 
1358, 1166, 1124, 815; MS m/z 245 ([M + 1]+, 15), 244 (M+, 100), 216 (41), 201 (87). Anal. (C14H11O4) 
C, H. 
Biological assay. Enzymatic MAO-A and MAO-B activity of compounds was determined by a 
fluorimetric method following a previously described protocol.24 Briefly, 0.1 mL of sodium phosphate 
buffer (0.05 M, pH 7.4) containing various concentrations of the test drugs and appropriate amounts of 
recombinant hMAO-A or hMAO-B and adjusted to obtain in our experimental conditions the same 
reaction velocity in the presence of both isoforms were incubated for 15 min at 37 ºC in a flat-black-
bottom 96-well microtest plate placed in the dark fluorimeter chamber. After this incubation period, the 
reaction was started by adding (final concentrations) 200 μM of 10-acetyl-3,7-dihydroxyphenoxazine 
reagent (Amplex Red assay kit), 1 U/ml horseradish peroxidase and 1 mM p-tyramine. The production 
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of H2O2 and, consequently, of resorufin was quantified at 37 °C in a Multi-Detection microplate 
fluorescence reader (FLX800) based on the fluorescence generated (excitation, 545 nm, emission, 590 
nm) over a 15 min period, during which the fluorescence increased linearly. 
Control experiments were carried out simultaneously by replacing the test drugs (new compounds 
and reference inhibitors) with appropriate dilutions of the vehicles. In addition, the possible capacity of 
the above test drugs to modify the fluorescence generated in the reaction mixture due to non-enzymatic 
inhibition was determined by adding these drugs to solutions containing only the Amplex Red reagent in 
a sodium phosphate buffer. 
To determine the kinetic parameters of hMAO-A and hMAO-B (Km and Vmax), the corresponding 
enzymatic activity of both isoforms was evaluated (under the experimental conditions described above) 
in the presence of a number of p-tyramine concentrations. 
The specific fluorescence emission (used to obtain the final results) was calculated after subtraction 
of the background activity, which was determined from vials containing all components except the 
MAO isoforms, which were replaced by a sodium phosphate buffer solution. 
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